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Abstract We evaluated a 15% paste formulation of
ponazuril in outbred Swiss mice that were experimen-
tally infected with Eimeria vermiformis. Thirty, 8-week-
old female mice (approximately 20 g) were placed in one
group of 10 mice and one group of 20 mice. Mice in both
groups were gavaged with approximately 5,000 sporu-
lated oocysts of E. vermiformis on day 0. Mice in group
2 (n=10) were treated orally on days 3 and 4 with
ponazuril (suspended in 30% propylene glycol) at the
rate of 20 mg/kg. Mice in group 1 (n=20) were gavaged
with a similar volume of 30% propylene glycol. Rates of
oocyst passage (oocysts/g feces) were determined on
day 10 (peak patency) for treated and nontreated mice
using a fecal aliquot oocyst counting technique. Oocysts
were not observed in the feces of treated mice using the
aliquot technique. Control mice passaged oocysts at a
geometric mean rate of >104,000 oocysts/g feces.
Control mice also produced significantly less feces on
day 10. These results indicate that ponazuril is effective
against E. vermiformis under the conditions utilized in
this study, and that the E. vermiformis mouse model
could be useful in predicting the efficacy of new
anticoccidial drugs.
Introduction
Coccidiosis is a cosmopolitan disease in both food and
companion animals. Although the term coccidia gener-
ally refers to numerous related genera of apicomplexan
protozoan parasites, traditional reference to coccidiosis
implied that the causative agents were apicomplexan
protozoan parasites of the genera Eimeria or Isospora.
Numerous anticoccidial agents are available for the
treatment of livestock and poultry coccidiosis (Long
1990). However, there are few approved anticoccidial
medications for other species such as dogs and cats
(Lindsay and Blagburn 1991). Convenient and repre-
sentative animal models for the study of the biological
and chemotherapeutic aspects of coccidiosis would be
helpful in identifying effective candidate anticoccidial
medications in these and other host species.
Eimeria vermiformis is a pathogenic coccidium known
to infect several laboratory strains of Mus musculus
(Rose et al. 1997a). Numerous previous studies have
demonstrated that E. vermiformis can be an effective
model species for the study of the developmental,
pathogenetic, immunological, ultrastructural, and ge-
netic aspects of coccidiosis (Blagburn et al. 1982; Blag-
burn and Todd 1984, 1986; Rose et al. 1997b; Smith and
Hayday 2000).
Ponazuril is the sulfone derivative of toltrazuril, a
triazinetrione anticoccidial medication that is effective in
the treatment of coccidiosis caused by both Eimeria and
Isospora spp. in a variety of host species (Lech 2002).
Ponazuril also is the active ingredient in a paste for-
mulation approved for the treatment of equine proto-
zoal myeloencephalitis in horses (Furr et al. 2001). In the
present communication, we investigated the capability
of ponazuril to inhibit the development of E. vermifor-
mis in experimentally infected outbred Swiss mice. The
successful development of this model could result in its
use in the evaluation of other potentially effective anti-
coccidial agents.
Materials and methods
Source and propagation of E. vermiformis
Oocysts of E. vermiformis were maintained and propa-
gated periodically in outbred Swiss mice in the labora-
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tory of one of the authors (B.C.). Sporulated oocysts
were shipped to Auburn University in 2.5% potassium
dichromate (K2Cr2O7) solution. The K2Cr2O7 was re-
moved by repeated centrifugation and washing in
Hanks’ balanced salt solution. To acquire sufficient
numbers of oocysts for conducting the experiments re-
ported here, four female, 8-week-old Swiss mice (Harlan
Sprague Dawley, Indianapolis, Ind., USA) were each
gavaged with 2,000 sporulated oocysts. This inoculum
level was selected to obtain a maximum yield of oocysts
without the induction of clinical disease, and was based
on our previous experience with this parasite (Blagburn
and Todd 1984). For collection of F1 oocysts, mice were
placed in wire-bottomed cages on postinfection
days 8–12. Feces were collected in pans beneath the
cages to which 2.5% K2Cr2O7 was added. During pa-
tency, sample days were collected separately to deter-
mine on which collection day peak patency occurred.
The feces/K2Cr2O7 mixture for each day’s collection was
placed in 500 ml bottles and maintained for 7 days un-
der forced aeration to allow the oocysts to sporulate.
Oocysts were purified using a Sheather’s sucrose flota-
tion procedure (Hammond et al. 1968) and stored in
2.5% K2Cr2O7 solution at 4C for approximately
2 weeks before they were used. Prior to inoculation into
mice, the K2Cr2O7 was removed as previously described.
Oocysts were enumerated with the aid of a hemacy-
tometer.
Mice
Thirty female, 8-week-old mice were obtained from a
commercial supplier (Harlan/Sprague Dawley). Mice
were housed as groups of five in box cages containing
ground corn cobs as bedding (Harlan Teklad, Madison,
Wis., USA). Water and a standard laboratory ration
(Harlan Teklad) were provided ad libitum. Mice were
separated into two groups of 20 mice and 10 mice,
respectively. The mice weighed approximately 20 g at
the initiation of the experiment.
Infection with E. vermiformis and treatment
with ponazuril
On study day 0, mice in both groups were inoculated
by oral gavage with 5,000 sporulated E. vermiformis
oocysts in approximately 0.25 ml of HBSS. This
challenge infection rate was selected to provide a
moderate pathogen challenge without inducing high
mortality (Blagburn and Todd 1984). A 15% paste
formulation of ponazuril (Marquis) was obtained from
Bayer HealthCare, Shawnee Mission, Kan. (Lech
2002). For treatment of mice, a suspension of pon-
azuril in a 30% solution of propylene glycol was
created by adding 80 mg of formulated paste to 3 ml
of 30% propylene glycol. On each of days 3 and 4
after infection, group 2 mice (n=10) were each treated
orally with ponazuril in propylene glycol at a dosage
of 20 mg/kg (volume=0.1 ml). Group 1 mice were
each treated orally with an equal volume (approxi-
mately 0.1 ml) of 30% propylene glycol without pon-
azuril. Dosing was achieved by adding the ponazuril
suspension and propylene glycol diluent to a 1 cc
tuberculin syringe to which a 22 gauge gavage needle
was attached. During the propagation procedure, we
observed that day 10 was the day on which the
greatest number of E. vermiformis oocysts were pas-
saged by infected mice. This is also consistent with our
previous research (Blagburn and Todd 1984). Conse-
quently, we elected to collect feces from all group 1
and group 2 mice on day 10 after infection (6 days
after the last treatment). For fecal collection, mice
were placed individually in plastic containers for
20 min. Fecal specimens were weighed and then
transferred to plastic vials (Fisher Scientific, Suwanee,
Ga., USA) containing 1 ml of 2.5% K2Cr2O7 and
stored at room temperature (22C) until oocysts were
enumerated.
Oocyst enumeration/ponazuril efficacy determination
Fecal specimens collected on day 10 were examined for
E. vermiformis oocysts using a Sheather’s sucrose flo-
tation procedure. Briefly, the mixture of K2Cr2O7 and
feces were mixed thoroughly in a paraffinized cup. The
liquid was then poured through a tea strainer into a
second cup. The filtrate was added to a 16·100 mm
glass tube and centrifuged at 250 g for 5 min. A pipette
attached to a vacuum system was used to remove the
supernatant above the pelleted particulate debris.
Sheather’s sucrose (SG 1.20) was added to the tube and
mixed thoroughly with the debris. The tube was re-
turned to the centrifuge and filled with Sheather’s
sucrose to form a meniscus. A 23-mm square cover slip
was placed on the glass tube and the preparation was
again centrifuged for 10 min at approximately 60 g.
The cover slip was removed and placed on a 1·3’’ glass
slide.
Because of the high numbers of oocysts present in the
fecal specimens from control mice, an aliquot technique
was employed for the enumeration of E. vermiformis
oocysts. Six high-power (400·) fields were visualized in
the center of the cover slip and all oocysts present in the
six fields were counted. The fields that were counted
were located in the same positions on all of the slides.
The efficacy of ponazuril was determined by com-
paring the number of oocysts recovered from treated
versus control mice on day 10 using the following for-
mula: geometric mean number of oocysts recovered
from control mice minus geometric mean number of
oocysts from treated mice divided by the geometric
mean number of oocysts recovered from control mice
·100. Fecal and oocyst outputs were compared on
day 10 using Student’s t-test (SAS, Cary, N.C., USA).
All data were converted to log10 prior to statistical
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analysis. Determination of statistical significance was
based on a significance level of P<0.05.
Results and discussion
Treatment with ponazuril or propylene glycol appeared
safe since no adverse clinical sign that could be associ-
ated with the administration of either of these agents
was observed. One moribund mouse in the ponazuril-
treated group (group 2) was killed on study day 4. We
attributed the moribund state of this animal to esopha-
geal trauma induced by the gavage needle. A nontreated
mouse (group 1) was killed on study day 9 because of
ataxia which we attributed to signs of E. vermiformis-
induced coccidiosis. Day 9 is the time at which mice in
previous studies were observed to succumb to coccidio-
sis (Blagburn and Todd 1984). The remaining non-
treated mice appeared unkempt with poor quality hair
coats. They tended to huddle in groups in their respec-
tive cages. Mice treated with ponazuril appeared clini-
cally normal. All were active and had normal healthy
hair coats.
The results of E. vermiformis fecal oocyst counts on
study day 10 are presented in Table 1. Fecal samples
were successfully obtained from 18 nontreated (group
1) mice and 9 treated (group 2) mice on day 10. One
nontreated mouse did not defecate during the allotted
time. The geometric mean number of E. vermiformis
oocysts per gram of feces recovered from nontreated
mice exceeded 104,000 (range=10,773–549,990, Ta-
ble 1). Oocysts were not observed in the six-field
aliquots examined in any of the ponazuril-treated mice,
indicating that ponazuril was effective in inhibiting
development of E. vermiformis (P=0.0013). However,
because we did not examine each slide entirely, we
cannot state with certainty that oocysts were not
present in the feces of treated mice. The amount of
feces obtained from treated mice on study day 10 was
significantly greater than the amount of feces obtained
from nontreated mice (P=0.0041). This was probably
due to reduced appetite in nontreated mice and their
reduced food consumption. However, since we did not
measure food consumption for individual animals, we
cannot rule out other possible causes for the differences
in fecal output on day 10. Reduced food consumption
is a common clinical sign of coccidiosis in clinically ill
animals (Long 1990).
The results of the present study indicate that pon-
azuril is effective in the treatment of coccidiosis caused
Table 1 Day 10 fecal outputs
and oocyst counts from Eimeria
vermiformis infected mice
treated orally on days 3 and 4
after infection with either 30%
propylene glycol (group 1) or
ponazuril (20 mg/kg, group 2).
Feces were obtained from 18
control mice and nine treated
mice on day 10
a,b Means with different super-
scripts are significantly different
(P<0.05)
*Geometric mean no. of oo-
cysts from control miceGeo-
metric mean no. of oocysts
from treated mice · Geometric










Oocysts per gram of feces
based on aliquot count
Group 1 (nontreated)
1–1 776.0 0.08 549,990
1–2 35.0 0.11 18,039
1–3 19.0 0.10 10,773
1–4 415.0 0.37 63,532
1–5 124.0 0.14 50,200
1–6 183.0 0,08 129,701
1–7 242.0 0.07 196,079
1–8 97.0 0.02 274,995
1–9 176.0 0.06 165,655
1–10 93.0 0.20 26,366
1–11 230.0 0.06 216,481
1–12 324.0 0.12 153,029
1–13 655.0 0.12 309,364
1–14 197.0 0.06 185,420
1–15 102.0 0.19 30,421
1–16 358.0 0.10 202,986
1–17 139.0 0.09 87,561
1–18 557.0 0.16 197,387
Geometric mean 182.6 0.10a 104,240a
Group 2 (ponazuril)
2–1 0 0.31 0
2–2 0 0.23 0
2–3 0 0.18 0
2–4 0 0.17 0
2–5 0 0.07 0
2–6 0 0.14 0
2–7 0 0.23 0
2–8 0 0.42 0
2–9 0 0.36 0
Geometric mean 0 0.21b 0b
Efficacy* 100%
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by E. vermiformis. Because ponazuril was administered
after inoculation with E. vermiformis oocysts and during
active replication in the host, the observed results are
due to the therapeutic effects of this drug.
Ponazuril is the sulfone metabolite of toltrazuril and
is formed when the parent molecule is metabolized
within the host (Lech 2002). As mentioned previously,
either the parent molecule, toltrazuril, or ponazuril was
demonstrated previously to be effective against the
intracellular stages of numerous coccidia or coccidia-like
organisms (Haberkorn 1996; Daugschies 2000; Lindsay
et al. 2000; Lloyd and Smith 2001; Mundt et al. 2003);
therefore one could expect that ponazuril would also
possess a similar broad spectrum of activity. In fact,
specific studies indicate that ponazuril is effective against
Neospora caninum (also referred to as Hammondia
heydorni) and Isospora suis (Gottstein et al. 2001; Kalt-
hoff 2001; Mundt et al. 2003). Ponazuril was completely
effective when administered at 20 mg/kg 2 days after the
experimental inoculation of pigs with I. suis. Treatment
after 2 days inhibited further development of the para-
site, but did not prevent the development of lesions in
the gut (Kalthoff 2001). Results of the present study
appear to show complete efficacy, even though the drug
was initially administered 3 days after infection. Differ-
ences in this and the previous study were probably due
to differences in the length of the life cycle of I. suis and
E. vermiformis. Ponazuril or toltrazuril was also effective
against Toxoplasma gondii in experimentally infected
cats (Rommel et al. 1987) or N. caninum in mice
(Gottstein et al. 2001).
The results obtained using ponazuril and experi-
mental E. vermiformis infections in Swiss mice as de-
scribed here are similar to the observed efficacies of
ponazuril or the parent molecule toltrazuril against
coccidia in numerous hosts. The methodologies that we
employed were convenient and straightforward and
could be reproduced easily in most research facilities.
The Swiss mouse/E. vermiformis model used in the
present study could be validly and conveniently em-
ployed to identify future effective anticoccidial agents.
This is especially important for other coccidial species
and in hosts for which few approved anticoccidial agents
exist.
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